Global Information
회사소개 | 문의 | 위시리스트

세계의 내분비질환 약제 시장(2020-2024년)

Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2020년 02월 상품 코드 356778
페이지 정보 영문 120 Pages
가격
US $ 2,500 ₩ 3,044,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,652,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,870,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,088,000 PDF by E-mail (Global license) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 내분비질환 약제 시장(2020-2024년) Endocrinology Drugs Market by Therapy Area and Geography - Forecast and Analysis 2020-2024
발행일 : 2020년 02월 페이지 정보 : 영문 120 Pages

세계 내분비질환 약제 시장은 2020-2024년간의 예측기간 중 7%의 연평균 복합 성장률(CAGR)로 성장을 지속하여 247억 8,000만 달러 규모에 이를 전망입니다. 내분비 장애 발생률 증가가 시장 성장요인 중 하나입니다. 비만과 내분비 장애의 관련성 또한 시장 성장을 촉진할 것으로 예상됩니다.

세계의 내분비질환 약제(Endocrinology Drugs) 시장에 대해 조사 분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인, 과제, 시장 기회, 주요 벤더 등에 대해 체계적인 정보를 제공합니다

목차

제1장 주요 요약

제2장 시장 상황

  • 시장 생태계

제3장 시장 규모

  • 시장 정의
  • 시장 부문 분석
  • 시장 규모(2019년)
  • 시장 전망 : 예측(2019-2024년)

제4장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대체품의 위협
  • 경쟁사의 위협
  • 시장 현황

제5장 시장 세분화 : 치료 분야별

  • 당뇨병 치료제 - 시장 규모와 예측(2019-2024년)
  • hGH - 시장 규모와 예측(2019-2024년)
  • 갑상선 호르몬 장애 - 시장 규모와 예측(2019-2024년)
  • 테스토스테론 보충 요법 - 시장 규모와 예측(2019-2024년)
  • 기타 - 시장 규모와 예측(2019-2024년)

제6장 고객 상황

제7장 지역별 상황

  • 지역별 세분화
  • 북미 - 시장 규모와 예측(2019-2024년)
  • 유럽 - 시장 규모와 예측(2019-2024년)
  • 아시아 - 시장 규모와 예측(2019-2024년)
  • 기타 지역 - 시장 규모와 예측(2019-2024년)
  • 주요 국가
  • 시장 기회 : 지역별

제8장 성장 촉진요인, 과제, 동향

  • 시장 성장 촉진요인
  • 시장의 과제
  • 시장 동향

제9장 벤더 전망

  • 개요
  • 벤더 상황
  • 상황 혁신

제10장 벤더 분석

  • 대상 벤더
  • 벤더의 시장 포지셔닝
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc

제11장 부록

  • 조사 범위
  • 달러의 통화 환산율
  • 조사 방법
  • 약어 리스트
LSH 20.02.12

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

Technavio has been monitoring the global endocrinology drugs market and it is poised to grow by USD 24.78 bn during 2020-2024, progressing at a CAGR of 7% during the forecast period. Our reports on global endocrinology drugs market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increase in incidence of endocrine disorders . In addition, association between obesity and endocrine disorders is anticipated to boost the growth of the global endocrinology drugs market as well.

Market Segmentation

Technavio's global endocrinology drugs market is segmented as below:

Therapy area

  • Diabetes Drugs
  • Thyroid Hormone Disorder Drugs
  • HGH
  • Testosterone Replacement Therapy
  • Others

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global endocrinology drugs market growth

This study identifies association between obesity and endocrine disorders as the prime reasons driving the global endocrinology drugs market growth during the next few years.

Prominent vendors in global endocrinology drugs market

We provide a detailed analysis of around 25 vendors operating in the global endocrinology drugs market, including some of the vendors such as Abbott Laboratories, AbbVie Inc., AstraZeneca Plc, Eli Lilly and Co., GlaxoSmithKline Plc, Groupe Sanofi, Merck & Co. Inc., Novartis International AG, Novo Nordisk AS and Pfizer Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Other 1

  • Market segments
  • Comparison by Other1 placement
  • Diabetes drugs - Market size and forecast 2019-2024
  • hGH - Market size and forecast 2019-2024
  • Thyroid hormone disorders - Market size and forecast 2019-2024
  • Testosterone replacement therapy - Market size and forecast 2019-2024
  • Others - Market size and forecast 2019-2024
  • Market opportunity by Other1

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Abbott Laboratories
  • AbbVie Inc.
  • AstraZeneca Plc
  • Eli Lilly and Co.
  • GlaxoSmithKline Plc
  • Groupe Sanofi
  • Merck & Co. Inc.
  • Novartis International AG
  • Novo Nordisk AS
  • Pfizer Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ billion)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Other1 placement - Market share 2019-2024 (%)
  • 23.Comparison by Other1 placement
  • 24.Diabetes drugs - Market size and forecast 2019-2024 ($ billion)
  • 25.Diabetes drugs - Year-over-year growth 2019-2024 (%)
  • 26.hGH - Market size and forecast 2019-2024 ($ billion)
  • 27.hGH - Year-over-year growth 2019-2024 (%)
  • 28.Thyroid hormone disorders - Market size and forecast 2019-2024 ($ billion)
  • 29.Thyroid hormone disorders - Year-over-year growth 2019-2024 (%)
  • 30.Testosterone replacement therapy - Market size and forecast 2019-2024 ($ billion)
  • 31.Testosterone replacement therapy - Year-over-year growth 2019-2024 (%)
  • 32.Others - Market size and forecast 2019-2024 ($ billion)
  • 33.Others - Year-over-year growth 2019-2024 (%)
  • 34. Market opportunity by Other1
  • 35.Customer landscape
  • 36.Market share by geography 2019-2024 (%)
  • 37.Geographic comparison
  • 38.North America - Market size and forecast 2019-2024 ($ billion)
  • 39.North America - Year-over-year growth 2019-2024 (%)
  • 40.Europe - Market size and forecast 2019-2024 ($ billion)
  • 41.Europe - Year-over-year growth 2019-2024 (%)
  • 42.Asia - Market size and forecast 2019-2024 ($ billion)
  • 43.Asia - Year-over-year growth 2019-2024 (%)
  • 44.ROW - Market size and forecast 2019-2024 ($ billion)
  • 45.ROW - Year-over-year growth 2019-2024 (%)
  • 46.Key leading countries
  • 47.Market opportunity by geography ($ billion)
  • 48.Impact of drivers
  • 49.Impact of challenges
  • 50.Landscape disruption
  • 51.Industry risks
  • 52.Vendors covered
  • 53.Market positioning of vendors
  • 54.Abbott Laboratories - Overview (1/3)
  • 55.Abbott Laboratories - Overview (2/3)
  • 56.Abbott Laboratories - Overview (3/3)
  • 57.Abbott Laboratories - Business segments
  • 58.Abbott Laboratories - Key offerings
  • 59.Abbott Laboratories - Key customers
  • 60.Abbott Laboratories - Segment focus
  • 61.AbbVie Inc. - Overview (1/3)
  • 62.AbbVie Inc. - Overview (2/3)
  • 63.AbbVie Inc. - Overview (3/3)
  • 64.AbbVie Inc. - Business segments
  • 65.AbbVie Inc. - Key offerings
  • 66.AbbVie Inc. - Key customers
  • 67.AbbVie Inc. - Segment focus
  • 68.AstraZeneca Plc - Overview (1/3)
  • 69.AstraZeneca Plc - Overview (2/3)
  • 70.AstraZeneca Plc - Overview (3/3)
  • 71.AstraZeneca Plc - Product and service
  • 72.AstraZeneca Plc - Key offerings
  • 73.AstraZeneca Plc - Key customers
  • 74.AstraZeneca Plc - Segment focus
  • 75.Eli Lilly and Co. - Overview (1/3)
  • 76.Eli Lilly and Co. - Overview (2/3)
  • 77.Eli Lilly and Co. - Overview (3/3)
  • 78.Eli Lilly and Co. - Business segments
  • 79.Eli Lilly and Co. - Key offerings
  • 80.Eli Lilly and Co. - Key customers
  • 81.Eli Lilly and Co. - Segment focus
  • 82.GlaxoSmithKline Plc - Overview (1/3)
  • 83.GlaxoSmithKline Plc - Overview (2/3)
  • 84.GlaxoSmithKline Plc - Overview (3/3)
  • 85.GlaxoSmithKline Plc - Business segments
  • 86.GlaxoSmithKline Plc - Key offerings
  • 87.GlaxoSmithKline Plc - Key customers
  • 88.GlaxoSmithKline Plc - Segment focus
  • 89.Groupe Sanofi - Overview (1/3)
  • 90.Groupe Sanofi - Overview (2/3)
  • 91.Groupe Sanofi - Overview (3/3)
  • 92.Groupe Sanofi - Business segments
  • 93.Groupe Sanofi - Key offerings
  • 94.Groupe Sanofi - Key customers
  • 95.Groupe Sanofi - Segment focus
  • 96.Merck & Co. Inc. - Overview (1/3)
  • 97.Merck & Co. Inc. - Overview (2/3)
  • 98.Merck & Co. Inc. - Overview (3/3)
  • 99.Merck & Co. Inc. - Business segments
  • 100.Merck & Co. Inc. - Key offerings
  • 101.Merck & Co. Inc. - Key customers
  • 102.Merck & Co. Inc. - Segment focus
  • 103.Novartis International AG - Overview (1/3)
  • 104.Novartis International AG - Overview (2/3)
  • 105.Novartis International AG - Overview (3/3)
  • 106.Novartis International AG - Business segments
  • 107.Novartis International AG - Key offerings
  • 108.Novartis International AG - Key customers
  • 109.Novartis International AG - Segment focus
  • 110.Novo Nordisk AS - Overview (1/3)
  • 111.Novo Nordisk AS - Overview (2/3)
  • 112.Novo Nordisk AS - Overview (3/3)
  • 113.Novo Nordisk AS - Business segments
  • 114.Novo Nordisk AS - Key offerings
  • 115.Novo Nordisk AS - Key customers
  • 116.Novo Nordisk AS - Segment focus
  • 117.Pfizer Inc. - Overview (1/3)
  • 118.Pfizer Inc. - Overview (2/3)
  • 119.Pfizer Inc. - Overview (3/3)
  • 120.Pfizer Inc. - Business segments
  • 121.Pfizer Inc. - Key offerings
  • 122.Pfizer Inc. - Key customers
  • 123.Pfizer Inc. - Segment focus
  • 124.Currency conversion rates for US$
  • 125.Research Methodology
  • 126.Validation techniques employed for market sizing
  • 127.Information sources
  • 128.List of abbreviations
Back to Top
전화 문의
F A Q